Overview

Study to Determine Potential for Drug-drug Interactions When Co-administering Deupirfenidone (LYT-100) and Nintedanib

Status:
NOT_YET_RECRUITING

Trial end date:
2025-03-01

Target enrollment:

Participant gender:

Summary

This is a trial of up to 60-day duration for safety, tolerability, and pharmacokinetics in healthy volunteers administered deupirfenidone (LYT-100) alone or in combination with nintedanib .

Phase:

PHASE1

Details

Lead Sponsor:

PureTech

Collaborator:

Novotech (Australia) Pty Limited

Treatments:

nintedanib
pirfenidone